A study to learn the effects of ripretinib (study drug) on how midazolam behaves in the body of people with advanced gastrointestinal stromal tumor

2022-501477-40-00 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 25 Jun 2024 · Status Ongoing, recruitment ended · 3 EU/EEA countries · 6 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 22
Countries 3
Sites 6

Advanced Gastrointestinal Stromal Tumor

Key facts

Sponsor
Deciphera Pharmaceuticals Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
25 Jun 2024 → ongoing
Decision date (initial)
2023-08-28
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Gastrointestinal Stromal Tumor

VersionLevelCodeTermSystem organ class
21.1 PT 10051066 Gastrointestinal stromal tumour 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Deciphera Pharmaceuticals Inc.

Sponsor organisation
Deciphera Pharmaceuticals Inc.
Address
200 Smith Street
City
Waltham
Postcode
02451-0099
Country
United States

Scientific contact point

Organisation
Deciphera Pharmaceuticals Inc.
Contact name
Clinical trial information

Public contact point

Organisation
Deciphera Pharmaceuticals Inc.
Contact name
Clinical trial information

Locations

3 EU/EEA countries · 6 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruitment ended 6 1
Netherlands Ongoing, recruitment ended 6 1
Spain Ongoing, recruitment ended 10 4
Rest of world 0

Investigational sites

Italy

1 site · Ongoing, recruitment ended
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
U.O. Oncologia Medica, Regione Gonzole 10, 10043, Orbassano

Netherlands

1 site · Ongoing, recruitment ended
Leids Universitair Medisch Centrum (LUMC)
Oncology, Albinusdreef 2, 2333 ZA, Leiden

Spain

4 sites · Ongoing, recruitment ended
Hospital Universitari Vall D Hebron
Medical Oncology, Edificio Materno-Infantil, Passeig De La Vall D'hebron 119-129, Barcelona
Fundacion Instituto Valenciano De Oncologia
Medical Oncology, Calle Professor Beltran Baguena 8, 46009, Valencia
Fundacion Para La Investigacion Biomedica Hospital Clinico San Carlos
Medical Oncology, Calle Del Profesor Martin Lagos, 28040, Madrid
University Hospital Virgen Del Rocio S.L.
Medical Oncology, Avenida De Manuel Siurot S/n, 41013, Sevilla

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2024-06-25 2025-02-21 2025-06-26
Netherlands 2024-07-29 2025-02-13 2025-06-26
Spain 2024-07-03 2024-07-17 2025-06-26

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-05-17 Spain Acceptable
2023-08-22
2023-08-28
2 SUBSTANTIAL MODIFICATION SM-1 2023-11-30 Spain Acceptable
2024-02-21
2024-02-21
3 SUBSTANTIAL MODIFICATION SM-2 2024-10-29 Spain Acceptable
2025-02-04
2025-02-04
4 SUBSTANTIAL MODIFICATION SM-3 2025-10-02 Spain Acceptable
2025-11-13
2025-11-17